Publication | Closed Access

Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study

Week ResultsTreatment And PreventionHuman RetrovirusAntiviral TherapyDolutegravir Versus RaltegravirHiv-1 InfectionAntiviral DrugHivMedicineEpidemiologyAids Pathogenesis